Industry | |
---|---|
Founded | 1997 |
Headquarters | Basel, Switzerland |
Area served | Worldwide |
Key people | Othmar Pfannes (Founder & CEO) |
Products | https://www.genedata.com/products-services |
Number of employees | ~400 |
Website | https://www.genedata.com/ |
Genedata is a bioinformatics company that develops enterprise software solutions to accelerate biopharmaceutical research and development. Founded in 1997 by Othmar Pfannes, Genedata has since grown to approximately 400 employees. Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo positioning the company in the heart of biopharma clusters around the globe.
Today, top 25 biopharmaceutical enterprises, innovative biotechnology companies, and scientific research institutions use the Genedata Biopharma Platform to increase the efficiency of their R&D operations. With its knowledgeable scientific experts, modular software portfolio, and collaborative approach, Genedata helps companies to more efficiently discover, develop, characterize, and manufacture innovative biotherapeutics of all modalities including antibodies, cell and gene therapies (CGTs), RNA, and vaccines.
Genedata's solutions drive digitalization, automation, standardization, and data FAIRness while complying with regulatory standards. [1]
In July 2024, Genedata joined the Danaher Group.
Genedata developed its first product for drug target discovery in 1998.The Genedata Biopharma Platform encompasses purpose-built workflow and analysis systems that support discovery, development, and translational research, as well as technology-focused analytical workflows. These systems can be used either individually or together to connect distinct data streams within organizations. [2]
Screener – For assay data analytics and management in discovery and development [3]
Expressionist – For MS-based characterization and QC of biotherapeutics [4]
Selector – For NGS-based target discovery, bioprocess development, and QC of biotherapeutics [5]
Biologics – For covering the end-to-end biotherapeutics discovery workflow for all modalities [6]
Profiler – For translational research and precision medicine development [7]
Bioprocess – For bioprocess development workflows [8]
Chromatics – For integrated chromatography data management and analysis (To be released in 2025)
Proteomics is the large-scale study of proteins. Proteins are vital macromolecules of all living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.
A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
High-throughput screening (HTS) is a method for scientific discovery especially used in drug discovery and relevant to the fields of biology, materials science and chemistry. Using robotics, data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests. Through this process one can quickly recognize active compounds, antibodies, or genes that modulate a particular biomolecular pathway. The results of these experiments provide starting points for drug design and for understanding the noninteraction or role of a particular location.
Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming.
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.
Discovery science is a scientific methodology which aims to find new patterns, correlations, and form hypotheses through the analysis of large-scale experimental data. The term “discovery science” encompasses various fields of study, including basic, translational, and computational science and research. Discovery-based methodologies are commonly contrasted with traditional scientific practice, the latter involving hypothesis formation before experimental data is closely examined. Discovery science involves the process of inductive reasoning or using observations to make generalisations, and can be applied to a range of science-related fields, e.g., medicine, proteomics, hydrology, psychology, and psychiatry.
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
A Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials in clinical research. The system maintains and manages planning, performing and reporting functions, along with participant contact information, tracking deadlines and milestones.
Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services.
GC Biopharma [Green Cross Corporation] is a biopharmaceutical company headquartered in Yongin, South Korea.
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.
Optimer ligands are short synthetic oligonucleotide molecules composed of DNA or RNA that bind to a specific target molecule. They are engineered to bind their target molecules with affinity typically in the low nanomolar range. Optimers can be used as antibody mimetics in a range of applications, and have been optimized to increase their stability, reduce their molecular weight, and offer increased scalability and consistency in manufacture compared to standard aptamer molecules.
Sphere Fluidics is a Cambridge(UK)-based Life Sciences R&D company that specializes in biopharmaceutical discovery and development, cell therapy engineering, bioproduction and synthetic biology, analysis and isolation. The company is reported to own 25 patented products that include instruments, biochips, and specialist chemicals.
Host cell proteins (HCPs) are process-related protein impurities that are produced by the host organism during biotherapeutic manufacturing and production. During the purification process, a majority of produced HCPs are removed from the final product. However, residual HCPs still remain in the final distributed pharmaceutical drug. Examples of HCPs that may remain in the desired pharmaceutical product include: monoclonal antibodies (mAbs), antibody-drug-conjugates (ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuticals.
Jane Osbourn, OBE, is a scientist and former chair of the UK BioIndustry Association.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Rentschler Biopharma SE is a contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.